Epizyme Announces Third Quarter 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
RBC Affirms Epizyme (EPZM) at 'Outperform' as Ttazemetostat Enrollment Continues
November 9, 2015 12:43 PM ESTRBC Captial affirms Epizyme (Nasdaq: EPZM) at Outperform with a price target of $39 following Q3 results and update issued earlier.
Analyst Simos Simeonidis noted the following:
Enrollment continues in 150-patient Phase II study in NHL in Europe: On their 3Q15 earnings call this morning, management stated that plans remain on track for tazemetostat's Phase II programs. Patients are currently being enrolled in the 5-arm,... More
Epizyme (EPZM) Tops Q3 EPS by 3c
November 9, 2015 6:30 AM ESTEpizyme (NASDAQ: EPZM) reported Q3 EPS of ($0.56), $0.03 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $358 thousand versus the consensus estimate of $5.42 million.
For earnings history and earnings-related data on Epizyme (EPZM) click here.
... More